How to buy Corvus Pharmaceuticals stock - 13 April

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Corvus Pharmaceuticals stock

Own Corvus Pharmaceuticals stock in just a few minutes.

Corvus Pharmaceuticals, Inc is a biotechnology business based in the US. Corvus Pharmaceuticals shares (CRVS) are listed on the NASDAQ and all prices are listed in US Dollars. Corvus Pharmaceuticals employs 42 staff and has a market cap (total outstanding shares value) of USD$112.6 million.

How to buy shares in Corvus Pharmaceuticals

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Corvus Pharmaceuticals. Find the stock by name or ticker symbol: CRVS. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Corvus Pharmaceuticals reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Corvus Pharmaceuticals, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Corvus Pharmaceuticals. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Corvus Pharmaceuticals share price

Use our graph to track the performance of CRVS stocks over time.

Corvus Pharmaceuticals shares at a glance

Information last updated 2021-04-08.
52-week rangeUSD$2.04 - USD$5.28
50-day moving average USD$3.2666
200-day moving average USD$3.8142
Wall St. target priceUSD$8.63
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-1.559

Buy Corvus Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
N/A
A free way to invest in stocks, ETFs and crypto.
Robinhood
$0
Stocks, Options, ETFs, Gold/Commodities
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Corvus Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Corvus Pharmaceuticals financials

Gross profit TTM USD$0
Return on assets TTM -32.33%
Return on equity TTM -8.37%
Profit margin 0%
Book value $2.543
Market capitalisation USD$112.6 million

TTM: trailing 12 months

Shorting Corvus Pharmaceuticals shares

There are currently 1.6 million Corvus Pharmaceuticals shares held short by investors – that's known as Corvus Pharmaceuticals's "short interest". This figure is 24.2% up from 1.3 million last month.

There are a few different ways that this level of interest in shorting Corvus Pharmaceuticals shares can be evaluated.

Corvus Pharmaceuticals's "short interest ratio" (SIR)

Corvus Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Corvus Pharmaceuticals shares currently shorted divided by the average quantity of Corvus Pharmaceuticals shares traded daily (recently around 1.8 million). Corvus Pharmaceuticals's SIR currently stands at 0.89. In other words for every 100,000 Corvus Pharmaceuticals shares traded daily on the market, roughly 890 shares are currently held short.

However Corvus Pharmaceuticals's short interest can also be evaluated against the total number of Corvus Pharmaceuticals shares, or, against the total number of tradable Corvus Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Corvus Pharmaceuticals's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Corvus Pharmaceuticals shares in existence, roughly 40 shares are currently held short) or 0.0678% of the tradable shares (for every 100,000 tradable Corvus Pharmaceuticals shares, roughly 68 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Corvus Pharmaceuticals.

Find out more about how you can short Corvus Pharmaceuticals stock.

Corvus Pharmaceuticals share dividends

We're not expecting Corvus Pharmaceuticals to pay a dividend over the next 12 months.

Corvus Pharmaceuticals share price volatility

Over the last 12 months, Corvus Pharmaceuticals's shares have ranged in value from as little as $2.04 up to $5.28. A popular way to gauge a stock's volatility is its "beta".

CRVS.US volatility(beta: 1.72)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Corvus Pharmaceuticals's is 1.7198. This would suggest that Corvus Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Corvus Pharmaceuticals overview

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is CPI-006, an anti-CD73 monoclonal antibody, which is in Phase I/Ib clinical trial that inhibits the production of adenosine and activate various immune cells, as Phase III clinical trial of CPI-006 for COVID-19. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase Ib/II clinical trial for adenosine, an immune checkpoint. Its preclinical stage products include CPI-182, an antibody to block neutrophil function and migration, and myeloid derived suppressor cells; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals for the development its pipeline of targeted investigational medicines. The company was incorporated in 2014 and is based in Burlingame, California.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site